Lonza plans to construct a new 100,000 square foot facility for viral and immunotherapy development and manufacturing in the Houston, Texas area, complete with a fully segregated fill/finish suite. This new facility will more than double Lonza's capacity for the production of viral gene and virally modified therapeutics.

The multipurpose facility is expected to come on line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of European Medicines Agency-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.

Source: Lonza